Pharmacyclics Management Discusses Q4 2012 Results - Earnings Call Transcript

Pharmacyclics (PCYC)

Q4 2012 Earnings Call

September 06, 2012 4:30 pm ET

Executives

Rainer M. Erdtmann - Principal Accounting Officer, Vice President of Finance & Administration and Secretary

Robert W. Duggan - Chairman and Chief Executive Officer

Mahkam Zanganeh - Chief Operating Officer

Jesse Seton McGreivy - Vice President of Clinical Science

Joseph J. Buggy - Vice President of Research

Analysts

Michael J. Yee - RBC Capital Markets, LLC, Research Division

Brian Skorney - Brean Murray, Carret & Co., LLC, Research Division

Alan Carr - Needham & Company, LLC, Research Division

Michael G. King - Rodman & Renshaw, LLC, Research Division

Howard Liang - Leerink Swann LLC, Research Division

Geoffrey C. Porges - Sanford C. Bernstein & Co., LLC., Research Division

Joshua Schimmer - Lazard Capital Markets LLC, Research Division

Brian Lian - SunTrust Robinson Humphrey, Inc., Research Division

Presentation

Operator

Greetings, and welcome to the Pharmacyclics Fourth Quarter and Fiscal Year End 2012 Conference Call. [Operator Instructions] A brief question and answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Ramses Erdtmann, Vice President, Finance for Pharmacyclics. Thank you. Mr. Erdmann, you may begin.

Rainer M. Erdtmann

Yes. Thank you, Robin. Good afternoon, and thank you for joining us for our conference call today. With me on the call today and available to answer questions are our CEO and Chairman of the Board, Bob Duggan; our Chief Operating Officer, Dr. Maky Zanganeh; our Executive Vice President, Paula Boultbee; our Executive Vice President of Finance, Josh Brumm; Dr. Jesse McGreivy, our Vice President of Clinical Science; Dr. Maria Fardis, our Vice President of Alliance and Global Project Management; and our Vice President of Research, Dr. Joe Buggy.

If you liked this article you might like

Johnson & Johnson Looks for New Deal That's Just Right

The Nominees for Best Biopharma CEO of 2015 Are...

Jim Cramer's 'Mad Money' Recap: Here's How Oil, the Fed and China Pushed Markets Up

AXON, REGN, BURL, FIVE: Jim Cramer's Views

The 10 Biggest U.S. M&A Deals in 2015